Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
ASCO 2022 – Wrap Up
ASCO 2022 – Wrap-Up
Wrap-Up
DESTINY-Breast04 Compared T-DXd with TPC in Patients with HER2-Low Breast Cancer
ASCO 2022 – Wrap-Up
DESTINY-Breast04 is the first trial comparing outcomes with trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients with HER2-low metastatic breast cancer treated with 1 or 2 prior lines of chemotherapy.
Read More ›
Wrap-Up
TROPiCS-02 Primary Results: Sacituzumab Govitecan versus Treatment of Physician’s Choice in Patients with Advanced Breast Cancer
ASCO 2022 – Wrap-Up
The TROPiCS-02 study aims to confirm optimal treatment choice in patients with hormone receptor–positive/HER2-negative metastatic breast cancer whose disease progresses after having received endocrine therapy (ET) plus cyclin-dependent kinase (CDK)4/6 inhibitor.
Read More ›
Wrap-Up
Ribociclib Efficacious in Patients with Unresectable or HR-Positive/HER2-Negative Metastatic Breast Cancer Receiving Fulvestrant or Exemestane After Not Responding to Prior Treatments
ASCO 2022 – Wrap-Up
Patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer who had previously advanced on any cyclin-dependent kinase (CDK)4/6 inhibitor plus any endocrine therapy (ET) showed a substantial progression-free survival (PFS) advantage in the ribociclib-treated cohort.
Read More ›
Wrap-Up
Event-Free Survival by Residual Cancer Burden After Neoadjuvant Chemotherapy + Pembrolizumab for Early TNBC: KEYNOTE-522 Data
ASCO 2022 – Wrap-Up
Pembrolizumab plus chemotherapy increased event-free survival compared with chemotherapy alone, highlighting the relevance of neoadjuvant pembrolizumab therapy for improving survival in patients with early triple-negative breast cancer.
Read More ›
Wrap-Up
Revised Overall Survival and Progression-Free Survival Data from the FAKTION Study: Capivasertib + Fulvestrant in Metastatic, ER-Positive Breast Cancer
ASCO 2022 – Wrap-Up
Capivasertib plus fulvestrant’s PFS advantage benefitted a broader patient population, and overall survival (OS) data with improved biomarker analyses can now be reported.
Read More ›
Wrap-Up
Imlunestrant in ER-Positive Advanced Breast Cancer and Endometrial Endometrioid Cancer: EMBER Results
ASCO 2022 – Wrap-Up
Updated data from the EMBER trial of imlunestrant, a new oral selective estrogen receptor degrader showing sustained inhibition of estrogen receptor (ER)-dependent gene transcription and cell proliferation, have been released.
Read More ›
Wrap-Up
Final Results from the Phase 3 ASCENT Study: Sacituzumab Govitecan versus TPC in Patients with Previously Treated, Metastatic TNBC
ASCO 2022 – Wrap-Up
Sacituzumab govitecan (SG) showed a significant survival benefit over single-agent chemotherapy treatment of physician’s choice (TPC) in the pivotal phase 3 ASCENT trial.
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us